AquaBounty seeks overseas expansion, anticipating global demand for GMO AquAdvantage salmon

af b bdef c a extra large
AquaBounty GMO salmon

For more than two decades, AquaBounty has been developing its genetically modified AquAdvantage salmon, which the company plans to grow in land-based recirculating aquaculture systems (RAS).

Since the company gained regulatory approval, and finally had an import alert lifted by the U.S. Food and Drug Administration in May, the it has been busy growing the first batches of genetically modified salmon at its land-based facility in Indiana.

Now that its salmon has started its growing process, the company is already setting its sights on developing markets for the product, both in the United States and abroad.

“We’ve begun conversations with a number of states in the U.S. in terms of where the next facility will be,” [AquaBounty CEO Sylvia Wulf said]. “We’re looking at probably three to five different sites in the U.S., we’re looking at additional sites in Canada as well.”

Wulf said the company also aspires to take its aquaculture model overseas …. “We have approval for field trials in China, and the Chinese government has been very receptive in trying to navigate the regulatory approval process.”

The company has also begun – and is near completion – of field trials in Brazil, and is also exploring facilities in Israel ….

Read full, original article: AquaBounty aiming to build new RAS sites overseas

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-May-7-2026-12_16_37-PM-2
Viewpoint: Are cancer rates ‘skyrocketing’ as RFK, Jr. and MAHA claim? The evidence says mostly the opposite
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
Screenshot-2026-04-22-at-10.46.29-AM
Viewpoint: How to counter science disinformation? Science journalist offers 12 practical tips
Picture1-14
When superbugs threaten vulnerable children: Can AI help solve antibiotic resistance?
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
ChatGPT-Image-May-12-2026-08_39_41-PM
GLP podcast: Big Pharma, Big Ag, Big Food—health harming industries or life-saving innovators?
bigstock opioids on chalkboard with rol
GLP podcast: 'Safe injection sites': enabling drug addiction or saving lives?

Sorry. No data so far.

glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.